156 related articles for article (PubMed ID: 29934062)
1. An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
Burke JM; Shustov A; Essell J; Patel-Donnelly D; Yang J; Chen R; Ye W; Shi W; Assouline S; Sharman J
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):e327-e331. PubMed ID: 29934062
[TBL] [Abstract][Full Text] [Related]
2. An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Andorsky DJ; Kolibaba KS; Assouline S; Forero-Torres A; Jones V; Klein LM; Patel-Donnelly D; Smith M; Ye W; Shi W; Yasenchak CA; Sharman JP
Br J Haematol; 2019 Jan; 184(2):215-222. PubMed ID: 30183069
[TBL] [Abstract][Full Text] [Related]
3. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.
Sharman J; Hawkins M; Kolibaba K; Boxer M; Klein L; Wu M; Hu J; Abella S; Yasenchak C
Blood; 2015 Apr; 125(15):2336-43. PubMed ID: 25696919
[TBL] [Abstract][Full Text] [Related]
4. Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.
Awan FT; Thirman MJ; Patel-Donnelly D; Assouline S; Rao AV; Ye W; Hill B; Sharman JP
Leuk Lymphoma; 2019 Aug; 60(8):1972-1977. PubMed ID: 30633573
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Flinn IW; Bartlett NL; Blum KA; Ardeshna KM; LaCasce AS; Flowers CR; Shustov AR; Thress KS; Mitchell P; Zheng F; Skolnik JM; Friedberg JW
Eur J Cancer; 2016 Feb; 54():11-17. PubMed ID: 26707592
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.
Barr PM; Saylors GB; Spurgeon SE; Cheson BD; Greenwald DR; O'Brien SM; Liem AK; Mclntyre RE; Joshi A; Abella-Dominicis E; Hawkins MJ; Reddy A; Di Paolo J; Lee H; He J; Hu J; Dreiling LK; Friedberg JW
Blood; 2016 May; 127(20):2411-5. PubMed ID: 26968534
[TBL] [Abstract][Full Text] [Related]
7. Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of
Walker AR; Byrd JC; Blachly JS; Bhatnagar B; Mims AS; Orwick S; Lin TL; Crosswell HE; Zhang D; Minden MD; Munugalavadla V; Long L; Liu J; Pan Y; Oellerich T; Serve H; Rao AV; Blum WG
Clin Cancer Res; 2020 Nov; 26(22):5852-5859. PubMed ID: 32820015
[TBL] [Abstract][Full Text] [Related]
8. Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.
Ma X; Li L; Zhang L; Fu X; Li X; Wang X; Wu J; Sun Z; Zhang X; Feng X; Chang Y; Zhou Z; Nan F; Zhang J; Li Z; Zhang M
Drug Des Devel Ther; 2020; 14():275-284. PubMed ID: 32158186
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.
Harrington BK; Gardner HL; Izumi R; Hamdy A; Rothbaum W; Coombes KR; Covey T; Kaptein A; Gulrajani M; Van Lith B; Krejsa C; Coss CC; Russell DS; Zhang X; Urie BK; London CA; Byrd JC; Johnson AJ; Kisseberth WC
PLoS One; 2016; 11(7):e0159607. PubMed ID: 27434128
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
11. A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
Eyre TA; Hildyard C; Hamblin A; Ali AS; Houlton A; Hopkins L; Royston D; Linton KM; Pettitt A; Rule S; Cwynarski K; Barrington SF; Warbey V; Wrench D; Barrans S; Hirst CS; Panchal A; Roudier MP; Harrington EA; Davies A; Collins GP
Hematol Oncol; 2019 Oct; 37(4):352-359. PubMed ID: 31385336
[TBL] [Abstract][Full Text] [Related]
12. Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome.
Jorda R; Krajčovičová S; Králová P; Soural M; Kryštof V
Eur J Med Chem; 2020 Oct; 204():112636. PubMed ID: 32731189
[TBL] [Abstract][Full Text] [Related]
13. Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
Yoshimoto T; Hayashi T; Kondo T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2018 Aug; 33(8):1513-1519. PubMed ID: 29669173
[TBL] [Abstract][Full Text] [Related]
14. Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.
Danilov AV; Herbaux C; Walter HS; Hillmen P; Rule SA; Kio EA; Karlin L; Dyer MJS; Mitra SS; Yi PC; Humeniuk R; Huang X; Zhou Z; Bhargava P; Jürgensmeier JM; Fegan CD
Clin Cancer Res; 2020 Jun; 26(12):2810-2818. PubMed ID: 32156743
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
Friedberg JW; Mahadevan D; Cebula E; Persky D; Lossos I; Agarwal AB; Jung J; Burack R; Zhou X; Leonard EJ; Fingert H; Danaee H; Bernstein SH
J Clin Oncol; 2014 Jan; 32(1):44-50. PubMed ID: 24043741
[TBL] [Abstract][Full Text] [Related]
16. Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma.
Gordon LI; Kaplan JB; Popat R; Burris HA; Ferrari S; Madan S; Patel MR; Gritti G; El-Sharkawi D; Chau I; Radford JA; Pérez de Oteyza J; Zinzani PL; Iyer S; Townsend W; Karmali R; Miao H; Proscurshim I; Wang S; Wu Y; Stumpo K; Shou Y; Carpio C; Bosch F
Clin Cancer Res; 2020 Jul; 26(14):3546-3556. PubMed ID: 32327472
[TBL] [Abstract][Full Text] [Related]
17. Pan- and Isoform-specific Inhibition of the Bromodomain and Extra-terminal Proteins and Evaluation of Synergistic Potential With Entospletinib in Canine Lymphoma.
Kong W; Sender S; Perez SV; Sekora A; Ruetgen B; Junghanss C; Nolte I; Murua Escobar H
Anticancer Res; 2020 Jul; 40(7):3781-3792. PubMed ID: 32620617
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
Walter HS; Rule SA; Dyer MJ; Karlin L; Jones C; Cazin B; Quittet P; Shah N; Hutchinson CV; Honda H; Duffy K; Birkett J; Jamieson V; Courtenay-Luck N; Yoshizawa T; Sharpe J; Ohno T; Abe S; Nishimura A; Cartron G; Morschhauser F; Fegan C; Salles G
Blood; 2016 Jan; 127(4):411-9. PubMed ID: 26542378
[TBL] [Abstract][Full Text] [Related]
19. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).
Gordon LI; Karmali R; Kaplan JB; Popat R; Burris HA; Ferrari S; Madan S; Patel MR; Gritti G; El-Sharkawi D; Chau FI; Radford J; de Oteyza JP; Zinzani PL; Iyer SP; Townsend W; Miao H; Proscurshim I; Wang S; Katyayan S; Yuan Y; Zhu J; Stumpo K; Shou Y; Carpio C; Bosch F
Oncotarget; 2023 Jan; 14():57-70. PubMed ID: 36702329
[TBL] [Abstract][Full Text] [Related]
20. SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.
Poe JC; Jia W; Di Paolo JA; Reyes NJ; Kim JY; Su H; Sundy JS; Cardones AR; Perez VL; Chen BJ; Chao NJ; Cardona DM; Saban DR; Sarantopoulos S
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]